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rect cost of asthma. METHODS: Data were drawn from the
2001 Medstat-Marketscan claims database. Medstat is a claims-
based database with over ﬁve-million members, representing an
employed population plus dependents. Individuals with asthma
were deﬁned as having at least two outpatient or one inpatient
event with a primary diagnosis of asthma (ICD-9 code 493).
Direct costs include expenditures for outpatient and inpatient
services and prescription drugs. Indirect costs include time lost
from work, short term disability and workers compensation.
RESULTS: The sample included 31,067 individuals with asthma
and 385,883 individuals without. Persons with asthma were sig-
niﬁcantly more likely to have paid absence from work (16.5%
vs. 5.2%), and when absences occur, they were 10.9% longer.
Similarly, persons with asthma are more likely to receive dis-
ability payments (8.6% vs. 2.0%), although the mean payments
are not statistically different. Persons with asthma are also more
likely to receive workers compensation payments (5.1% vs.
1.5%) which are signiﬁcantly more expensive ($7851 vs. $7073).
Overall mean expenditures for inpatient and outpatient care
were $311, the majority attributable to outpatient care ($207).
Inpatient stays were relatively infrequent, although expensive
when they occurred with a mean cost of $4736. CONCLUSION:
Asthma is a high cost chronic illness in employer populations.
Strategies to identify and manage high cost individuals may lead
to cost savings. However, asthma is an illness where total indi-
rect costs ($181) are an unusually higher percentage of the total
cost of illness, so much of the economic burden of the illness is
bourn directly by employers. This suggests that employer based
asthma programs may be appropriate.
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A DYAD APPROACH TO QUALITY OF LIFE MEASUREMENT IN
CHILDREN WITH ASTHMA
Mirabelli C, Cousins M, Boydell K, Ungar WJ
The Hospital for Sick Children,Toronto, ON, Canada
OBJECTIVES: The assessment of health-related quality of life
(HRQOL) is an essential component of evaluations of health
status, physical functioning, response to treatment and disease
progression. The measurement of HRQOL in children with
asthma often relies on parents as proxy respondents. Yet, several
studies have shown poor to moderate correlations between
parent and child responses, questioning the validity of the parent
proxy response. This pilot study tests a dyad approach, where
parent and child are interviewed together. It was hypothesized
that the dyad interview, by bringing parent and child perspec-
tives together, would create a more detailed and accurate picture
of HRQOL in children with asthma. METHODS: Children clin-
ically diagnosed with asthma aged 8 to 15 and their primary
caregivers were recruited from the Hospital for Sick Children
Asthma Clinic. Sixteen parent and child dyads consented and
were administered the Health Utilities Index Mark II & III (HUI
II/III), the Pediatric Asthma Quality of Life Questionnaire
(PAQLQ), and the Pediatric Quality of Life Inventory (PedsQL).
A qualitative approach was used wherein parents and children
were encouraged to discuss each question together. Interviews
were audiotaped and transcripts were analyzed thematically.
RESULTS: Consistent with Grounded Theory methodology,
observations were indexed according to a priori and a posteri-
ori categories and subcategories. Theoretical saturation was
achieved. The data showed that parents were a valuable resource
in overcoming problems associated with inaccurate recall,
respondent bias, frustration, psychic discomfort, anxiety and
comprehension. CONCLUSIONS: A dyad approach provided
children with access to their parent as an important information
resource, as an enabler and as an extension of the child’s cogni-
tive skills. Pilot data suggested that the dyad is more likely to
capture multi-factorial aspects of pediatric HRQOL than inde-
pendent assessments of parent or child.
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CHOOSING AMONG DIFFERENT TYPES OF MATCHING
TECHNIQUES
Baser O
Medstat, Inc, Ann Arbor, MI, USA
OBJECTIVE: The diversity of procedure in pharmaceutical
research requires a guideline to choose appropriate matching
method. Coherent guidelines for practice are absent. In this
paper we evaluate the several matching techniques and provide
a guideline to choose the best. METHODS: We proposed the fol-
lowing ways to check for the balance: 1) Two sample t-statistic
between the mean of the treatment group for each explanatory
variables with the mean of these variables in the control group;
2) The mean difference as a percentage of the average standard
deviations; 3) Percent reduction bias in means of explanatory
variables after matching and initially; 4) Compare treatment and
control density estimates for the explanatory variables; and 5)
Compare the density estimates of the propensity scores of control
units with that of the treated units. RESULTS: Medstat Market
Scan data used to provide empirical examples. We examined 2
to 1 matching, nearest neighborhood matching (NNM) with
replacement, NNM without replacement, MM matching (MM),
MM with calibers, stratiﬁcation method, kernel matching and
radius matching. Comparing techniques according to the above
criteria yield that 2 to 1 and NNM without replacement pro-
vides the worst balance. The difference between the control and
treatment variables was signiﬁcant. To choose among the rest,
we estimated the average treatment effect according to each
matching procedures and calculated the deviation from the mean
of estimated average treatment effect. MM with calibers where
calibers is selected as a quarter of standard deviation of estimated
propensity score provides least deviation, there this procedure
was superior to the others. CONCLUSION: Sensitivity analysis
of the matching techniques is especially important since none of
the proposed methods in literature is a priori superior to the
others. The joint consideration offers a way to assess the robust-
ness of the estimates.
CARDIOVASCULAR DISEASE—Angina/Ischemia
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OBJECTIVES: This study compared diagnostic accuracy, time
spent in the emergency department/chest pain observation unit
(“ED/CPU”), medical costs, and litigation risk of alternative
diagnostic strategies for acute cardiac ischemia (ACI) in
ED/CPU. Rest single photon emission computed tomography
(SPECT) with an innovative cardiac imaging agent, BMIPP, was
compared to pre-admission standard of care in ED/CPU.
METHODS: A decision tree model was constructed for alterna-
tive diagnostic strategies based on comprehensive literature
review and expert panel input. Pre-admission standard of care 
is a complex scheme involving enzyme tests, ECG, X-ray, and
SPECT with other common cardiac imaging agents. Model para-
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meters (e.g., test sensitivities/speciﬁcities) were collected from lit-
erature and expert opinion. Medical service costs were estimated
using published Medicare statistics, or paid amounts from a large
claims database covering approximately two million lives in 
the US. Cost analyses were conducted both from Medicare’s per-
spective and private third party payers’ perspective. Breakeven
prices of BMIPP were calculated. All costs were adjusted to 2003
USD using CPI. RESULTS: Compared to pre-admission standard
of care, SPECT with BMIPP has lower false positive and false
negative rates. Equivocal ACI patients tested by SPECT with
BMIPP spend 19 hours less per visit in ED/CPU. The breakeven
price of BMIPP is $927 per test from private third party payers’
perspective; and $554 from Medicare’s perspective. The likeli-
hood of malpractice litigation associated with ACI misdiagnosis
is 60% less for SPECT with BMIPP. CONCLUSIONS: Adoption
of SPECT with BMIPP for the diagnosis of ACI in ED/CPU may
reduce health care costs to third party payers and employers,
decrease patient time spent in ED/CPU, improve the efﬁciency 
of ED/CPU, and reduce malpractice litigation risk. It may also
signiﬁcantly reduce costs and risks associated with chest pain
patients admitted to the hospital following equivocal diagnosis
in the ED/CPU setting.
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OBJECTIVES: Acute coronary syndromes (ACS) are a major
cause of morbidity and mortality in Western Europe, imposing
signiﬁcant costs on health care providers. This study aims to esti-
mate costs (including medications prescribed, intervention rates
and hospital utilization) and health outcomes of ACS during 
the ﬁrst year following diagnosis. Perspective of the health 
care provider is used throughout. Countries examined were the
United Kingdom (UK), France, Germany, Italy and Spain.
METHODS: Treatment pathways for ACS patients, including
investigations, revascularisation and medical management, 
were developed. Resource use was multiplied by the unit cost of
the resource for all interventions and, since these factors vary
between countries, country-speciﬁc inputs (where possible) from
2002 data were used. RESULTS: Estimated number of deaths in
the ﬁrst year following ACS diagnosis ranged from around
22,500 in Spain to over 90,000 in Germany. Although the
number of patients undergoing percutaneous coronary interven-
tion (PCI) is lower in the UK (9%) than the rest of Western
Europe (Germany was highest at 62%), differences are narrow-
ing, as the UK’s PCI rate is increasing more rapidly than that 
of other countries. Largest contributors to total costs are 
hospital stay (particularly intensive and coronary care units) 
and revascularisation procedures. Pharmaceuticals were esti-
mated at 14–25% of ACS total cost. Models were most 
sensitive to changes in ACS incidence, death rate before hospi-
talization, and hospital unit costs. Total cost of ACS in the UK
is estimated around 1.8€ billion, compared with 1.3€ billion in
France, 3.2€ billion in Germany, 2.9€ billion in Italy and 1.0€
billion in Spain. CONCLUSION: Morbidity and mortality, and
cost of ACS are substantial. ACS contributes a large proportion
towards total health care expenditure of Western European
economies. Differences in expenditure between countries can 
be accounted for by disparities in population, incidence and
resource use.
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OBJECTIVE: Consensus treatment guidelines recommend most
patients with acute coronary syndrome (ACS) receive antiplatelet
therapy, statins, and beta-blockers for prevention of secondary
events. The goal of this review was to examine prescribing pat-
terns of these agents from published naturalistic studies and
compare to guideline recommendations. METHODS: An OVID
Medline search was conducted from 1995 to 2004 to identify
published naturalistic studies of ACS treatment that contained
detailed drug utilization data. Drug utilization patterns were
examined for two aspects: associated therapeutic strategy
(medical therapy or percutaneous coronary intervention [PCI])
and initiation of drug therapy (acutely or as chronic therapy after
hospital discharge). RESULTS: Four sources that contained 
sufﬁcient details on drug utilization were identiﬁed. Data were
from US and worldwide studies. Beta-blockers had the highest
overall utilization (50–87% acute; 41–77% chronic). Statins
were administered to 43–57% of patients acutely and 44–68%
chronically. Insufﬁcient data were available to examine associ-
ated therapeutic strategy for beta-blockers and statins. Clopido-
grel use, with or without aspirin, ranged from 16–30% acutely.
In the subgroup of patients who received PCI, clopidogrel use in
the hospitalization period ranged from 51–83%. The percentage
of ACS patients who received clopidogrel chronically was
38–66%, however in the subgroup of patients who underwent
PCI, up to 83% received clopidogrel after hospital discharge.
Insufﬁcient data were available to examine duration of therapy.
CONCLUSIONS: Recent treatment guidelines recommend use
of beta-blockers, statins, and antiplatelet therapy in ACS
patients. Some of the data reviewed here predates the most recent
guidelines but they suggest a gap between the usual care setting
and treatment guidelines. The largest discrepancy appears to be
with chronic statin use and clopidogrel use in ACS patients who
do not undergo PCI. Few data regarding duration of therapy are
available. Continued guideline education and reinforcement
along with quality improvement measures are needed.
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OBJECTIVES: Long-term antiplatelet therapy is typically con-
sidered standard of care for secondary prevention of cardiac
events in acute coronary syndrome (ACS) patients. The Euro-
pean Society of Cardiology consensus treatment guidelines in
2002 support the use of clopidogrel in many of these patients.
The goal of this descriptive study was to examine clopidogrel
patterns of use in ACS patients in the UK. METHODS: The data
source was the IMS Health, Disease Analyzer Mediplus—UK
database. This database contains nearly two-million de-identi-
ﬁed patient records and 58 million prescriptions continuously
collected from approximately 560 participating general prac-
tices. The study time period was January 01, 1999 to November
30, 2003. The index ACS event was identiﬁed using ICD-10
codes for unstable angina and acute myocardial infarction.
Patients were included if they had at least six-months of data
both before and after the index ACS event, and at least one pre-
scription for clopidogrel after the event. RESULTS: A total of
9591 patients were included in the ACS cohort and 1110 had at
